RB 203
Alternative Names: RB-203Latest Information Update: 07 Feb 2024
At a glance
- Originator Radiance Biopharma
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 17 Jan 2024 Early research in Solid tumors in USA (Parenteral) (Radiance Biopharma Pipeline Prior to January 2024)